ENTRADA THERAPEUTICS
Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.
ENTRADA THERAPEUTICS
Social Links:
Industry:
Biotechnology Emergency Medicine Genetics Health Care Medical
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.entradatx.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
175.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag
Similar Organizations
AmbAgon Therapeutics
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
Cognos Therapeutics
Cognos Therapeutics is a developer of diagnostic and drug delivery devices to detect diseases and deliver drugs.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Emedgene
Emedgene provides data-driven AI solutions for genomic diagnostics and discovery at scale.
EnteroBiotix
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections.
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology options.
MiNDERA Corporation
MiNDERA Dx conducts research and development on non-invasive molecular testing for skin cancer and other skin diseases.
Neuron23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Spatial Genomics
Spatial Genomics is a developer of sequential fluorescence in situ hybridization (seqFISH) technology.
Vedanta Biosciences
Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.
Vico Therapeutics
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Wellington Management
Wellington Management investment in Series B - Entrada Therapeutics
TCG Crossover
TCG Crossover investment in Series B - Entrada Therapeutics
MRL Ventures Fund
MRL Ventures Fund investment in Series B - Entrada Therapeutics
MPM Capital
MPM Capital investment in Series B - Entrada Therapeutics
Greenspring Associates
Greenspring Associates investment in Series B - Entrada Therapeutics
CureDuchenne Ventures
CureDuchenne Ventures investment in Series B - Entrada Therapeutics
Redmile Group
Redmile Group investment in Series B - Entrada Therapeutics
Moore Strategic Ventures
Moore Strategic Ventures investment in Series B - Entrada Therapeutics
5AM Ventures
5AM Ventures investment in Series B - Entrada Therapeutics
Agent Capital
Agent Capital investment in Series B - Entrada Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-19 | Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer |
Official Site Inspections
http://www.entradatx.com Semrush global rank: 2.84 M Semrush visits lastest month: 5.7 K
- Host name: 165.227.248.71
- IP address: 165.227.248.71
- Location: Clifton United States
- Latitude: 40.8364
- Longitude: -74.1403
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07014
More informations about "Entrada Therapeutics"
Today we are proud to announce the launch of the …
Today we are proud to announce the launch of the Entrada Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program. Through this initiative, Entrada will award three U.S.-based ...See details»
Entrada Therapeutics | Who We Are
Creating an organization where diversity flourishes and our employees can belong takes ongoing attention and effort – and we know we can’t do it alone. We are proud to actively partner with organizations across Boston, Cambridge …See details»
DREAMS Grant Program - Entrada Therapeutics
Launched in 2023, Entrada DREAMS is a competitive annual grant program designed to fund efforts within the Duchenne muscular dystrophy community to better identify, understand and reach those who are currently …See details»
Careers at Entrada - Entrada Therapeutics
Learn more about working at Entrada.We are each unique in our experiences and backgrounds but unified in our approach – with each Entradan bringing a genuine care for patients and community. We proudly offer multiple Employee …See details»
Entrada Therapeutics Email Format | entradatx.com Emails
The most common Entrada Therapeutics email format is [first_initial] [last] (ex. [email protected]), which is being used by 93.9% of Entrada Therapeutics work email …See details»
Entrada Group Client Invoices: Sign in
This is a classified area. Access is permitted only to authorized personnel. Any violation will be prosecuted according to the national and international laws.See details»
In the inaugural year of Entrada’s DREAMS Grant Program
In the inaugural year of Entrada’s DREAMS Grant Program, we awarded $25,000 grants to three U.S.-based nonprofits—each working to better reach and understand underrepresented …See details»
Entrada Therapeutics · GitHub
Innovating to transform the treatment of devastating diseases through intracellular therapeutics. - Entrada TherapeuticsSee details»
Entrada Therapeutics | Facility Spotlight
Welcome to Entrada Welcome to the main elevator bank at Entrada! Our Endosomal Escape Vehicle or EEV™ platform is designed to enable the intracellular delivery of therapeutics to disease-causing targets within the cell.See details»
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing …See details»
Entrada Therapeutics: Revenue, Worth, Valuation & Competitors …
Organization entradatx.com Location Boston , Massachusetts , United States Ranking #3004 Industry BiotechSee details»
Entrada Therapeutics Information - RocketReach
Entrada Therapeutics is a Biotechnology Research company located in Boston, Massachusetts with $239.4 million in revenue and 204 employees. Find top employees, contact details and …See details»
Patients - Entrada Therapeutics
Patients and care partners are experts who have unique and important insights essential to the process of developing and delivering truly transformational therapies. We embrace the fact …See details»
Entrada Therapeutics | Entrada Therapeutics Announces the …
Prior to joining Entrada in April 2020, Dr. Cohen was Vice President of Legal Affairs at Repertoire Immune Medicines where he designed and led all facets of the legal, compliance and …See details»
Making Intracellular Therapeutics A Reality
Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases.See details»
Entrada Therapeutics | LinkedIn
Entrada Therapeutics | 29,104 followers on LinkedIn. Innovating to transform the treatment of devastating diseases through intracellular therapeutics. | Headquartered in Boston’s Seaport …See details»
Entrada Therapeutics - 2025 Company Profile & Team - Tracxn
Jul 6, 2025 Entrada Therapeutics - Developer of the biologics-based platform to treat rare diseases. Public Company. Raised a total funding of $175M over 3 rounds from 13 investors.See details»
Healthcare Innovation Consultancy | ENTRADA
ENTRADA is a strategic consultancy that creates breakthrough solutions for progressive healthcare and pharmaceutical enterprises, delivering sustainable, measurable impact to their …See details»
Entrada Therapeutics, Inc. (Entrada Therapeutics, Inc.) - 药物管线_ …
Jun 15, 2025 For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn. Forward-Looking StatementsThis press release contains express …See details»
Entrada Therapeutics | Clinical Studies
About Clinical Studies Entrada adapted the below information from materials developed by the Center for Information and Study on Clinical Research Participation, an independent non-profit …See details»